SA 57 – 10 mg

Brand:
Cayman
CAS:
1346169-63-8
Storage:
-20
UN-No:
Non-Hazardous - /

SA 57 is an inhibitor of fatty acid amide hydrolase (FAAH; IC50s = 1.9 and 3.2 nM for hFAAH and mFAAH, respectively), monoacylglycerol lipase (MAGL; IC50s = 1,400 and 410 nM for hMAGL and mMAGL, respectively) and α/β-hydrolase domain-containing protein 6 (mABHD6; IC50 = 850 nM).{38148} In vivo, SA 57, at doses ≥1.25 mg/kg, selectively inactivates mFAAH and, at a dose of 12.5 mg/kg, inactivates mMAGL and mABHD6 resulting in a 10-fold increase in their substrates. Administration of SA 57 (5 mg/kg, i.p.) to morphine-dependent mice alleviates withdrawal signs without eliciting cannabimimetic side effects.{38149}  

 

SKU: - Category:

Description

An inhibitor of FAAH, MAGL, and ABHD6; inhibits in vitro hFAAH, mFAAH, hMAGL, mMAGL, and mABHD6 (IC50s = 1.9, 3.2, 1,400, 410, and 850 nM, respectively); inhibits in vivo mFAAH (≥1.25 mg/kg), mMAGL (12.5 mg/kg), and mABHD6 (12.5 mg/kg); alleviates morphine withdrawal in mice


Formal name: 4-[2-(4-chlorophenyl)ethyl]-1-piperidinecarboxylic acid-2-(methylamino), 2-oxoethyl ester

Synonyms: 

Molecular weight: 338.8

CAS: 1346169-63-8

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Fatty Acid Metabolism||Product Type|Biochemicals|Small Molecule Inhibitors|Glycerolipid Lipases||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Lipid Biochemistry|Glycerolipids|Lipases||Research Area|Neuroscience|Cannabinoid Research|Endocannabinoids